Prostate Cancer

808

Review clinical trials related to Prostate Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

Background: Immunotherapy is a type of treatment that works by making the body s own immune system stronger. These treatments are used for cancers such as non small cell lung cancer (NSCLC); thymic carcinoma (TC); or metastatic castrate-resistant prostate cancer (mCRPC). But these cancers may still come back after treatment. Objective: To test a new immunotherapy drug (STAR0602), alone or combined with an approved drug (nivolumab), in people with NSCLC, mCRPC, or TC. Eligibility: People aged 18 years or older with NSCLC, mCRPC, or TC that did not respond to treatment or returned after treatment. Design: Participants will be screened. They will have blood and urine tests. They will have imaging scans and a test of their heart function. STAR0602 and nivolumab are given through a needle inserted into a vein (infusion). Participants will be treated in 28-day cycles. They will receive infusions of 1 or both drugs on the first and 15th day of each cycle. They will remain in the hospital for up to 5 days after their first 2 infusions of STAR0602. Imaging scans, blood tests, and other tests may be repeated during study visits. Participants may opt to have tissue samples (biopsies) taken from their tumors. Some blood and tissue samples may be used for genetic tests. Participants may continue getting STAR0602 for up to 2 years and nivolumab for up to 6 months. Participants will have an end-of-study visit within 1 month, and follow-up phone calls 1 month and 3 months, after they stop the study drug. Long-term follow-up calls and visits will continue every 3 to 6 months for up to 5 years.

Participants needed: 67
Trial details
Phase: Phase 1, Phase 2Age: 18-120Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Nov 6, 2026Locations: 1
Eligibility criteria

Participants must have histologically or cytologically confirmed NSCLC, mCRPC, o... [+19]

History of allergic reactions attributed to compounds of similar chemical or bio... [+19]

Status: Recruiting

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to other parts of the body or return after treatment. Better treatments are needed. Objective: To test a new drug (SX-682), combined with an approved drug (docetaxel, or DTX), in people with HNCs or prostate cancer. Eligibility People aged 18 years and older with an HNC or prostate cancer that has returned after treatment or has spread. Design: Participants will be screened. They will have blood tests, imaging scans, and a test of their heart function. A tissue sample (biopsy) of the tumor may be taken. Participants will take the study drugs in 3-week cycles. SX-682 is a tablet taken by mouth twice a day from Days 1 to 11 of each cycle. Participants will get a supply of the drug to take home. DTX is given on Day 8 of each cycle through a tube attached to a needle inserted into a vein in the arm. Participants will come to the clinic on Days 1 and 8 of every cycle. They will take both drugs for up to 6 cycles. Participants will have follow-up visits 1 week and 1 month after they finish taking the drugs. Follow-ups will continue every 3 months for 2 years. Then they will have phone or email check-ins twice a year until 5 years have passed.

Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 18-120Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Nov 6, 2026Locations: 1
Eligibility criteria

Age >= 18 years. [+29]

History of allergic reactions attributed to compounds of similar chemical or bio... [+11]

Status: Recruiting

Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring. However, 35% of men with this cancer will need treatment within 5 years because of tumor growth. Researchers want to know if a new vaccine that targets 3 anti-cancer proteins (TriAdeno) plus a drug (N-803) approved for bladder cancer can help stop prostate tumors from growing. Objective: To test TriAdeno and N-803 in people with early-stage prostate cancer. Eligibility: People aged 18 years and older with early-stage low- or medium-risk prostate cancer. Design: Participants will be screened. They will have a physical exam with blood tests. They will have a test of their heart function. They will have an imaging scan. They may have a rectal exam. TriAdeno is injected under the skin of the upper thigh; N-803 is injected under the skin of the abdomen. Participants will be treated in up to four 21-day cycles. They will get both injections on the first day of each cycle. Participants may opt to complete a memory aid: They may record all of their symptoms for 7 days after each injection. They may also complete a questionnaire about their prostate symptoms. Blood tests, imaging scans, and other tests will be repeated during the study. A tissue sample (biopsy) of the tumor will be collected during or after cycle 2; a second biopsy may be taken about 1 year later. Participants will have follow-up phone calls for 5 years....

Participants needed: 52
Trial details
Phase: Phase 2Age: 18-120Biological sex: MaleType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Nov 6, 2026Locations: 1
Eligibility criteria

Histologically confirmed diagnosis of organ confined, low- or intermediate-risk... [+19]

Prior treatment for PCa by surgery, radiation, local ablative (i.e., cryosurgery... [+14]

Status: Recruiting

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Background: \- Radiation is a common treatment for prostate cancer. It helps damage tumor cells and causes them to die. Radiation can be effective, but some tumors may be harder to treat with radiation or even with surgery. This happens to a small number of men who have either radiation or surgery for prostate cancer. Most men who have these hard-to-treat tumors do not know if the tumor has recurred only in the prostate or has spread to another area. Also, men whose prostate cancer has recurred only after radiation may have different treatment options. This study will use improved imaging studies to better understand why some men do not respond as well to initial radiation treatments. Objectives: \- To use detailed imaging studies to look at the results of local radiation therapy for prostate cancer. Eligibility: * Men at least 18 years of age who are scheduled to have radiation for prostate cancer. * Men at least 18 years of age whose prostate cancer has returned after earlier treatments. Design: * All participants will have a medical history and physical exam. Blood and urine samples will be collected. Imaging studies will be used to evaluate the cancer at the start of the study. * All participants will have an initial full magnetic resonance imaging (MRI) scan of the prostate. Tumor and healthy tissue samples will be collected. * Those whose cancer has recurred after treatment will discuss possible treatment options with the study doctors. * Participants who are scheduled to have radiation will have radiation therapy. This will be given according to the current standard of treatment. * After radiation, participants will have regular follow-up tests and imaging studies. They will have another full MRI scan 6 months after the end of radiation treatment.

Participants needed: 300
Trial details
Age: 18-120Biological sex: MaleType: ObservationalSponsor: National Cancer Institute (NCI)Updated: Nov 6, 2026Locations: 1
Eligibility criteria

men with untreated prostate cancer. [+13]

Patients unable to tolerate MRI (patients with pacemakers, cerebral aneurysm cli... [+8]

Status: Recruiting

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Monte Rosa Therapeutics, IncUpdated: Nov 5, 2026Locations: 14
Eligibility criteria

Age > 18 years [+10]

• Have received prior chemotherapy, definitive radiation, or biological cancer t... [+7]

Status: Recruiting

Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment

This study is being done at Duke Health and includes adult men who have been treated for localized prostate cancer. The goal is to see if it is feasible and acceptable to offer sex therapy by telehealth after prostate cancer treatment. All participants receive pelvic floor physical therapy and education about penile rehabilitation, including use of a vacuum erection device. Participants are randomly assigned to one of two groups. One group receives pelvic floor physical therapy plus telehealth sex therapy, with about ten sessions over six months. The other group receives pelvic floor physical therapy alone. Participants complete questionnaires about urinary and sexual health at the start of the study and over the next two years. Short interviews are also done at 6 and 12 months. Medicines for erectile function are prescribed as part of usual clinical care and are not part of the study treatment.

Participants needed: 30
Trial details
Age: 18+Biological sex: MaleType: InterventionalSponsor: Duke UniversityUpdated: Nov 6, 2026Locations: 1
Eligibility criteria

Age 18 years or older. [+6]

Any androgen deprivation therapy (ADT) given for prostate cancer treatment or pl... [+7]

Status: Recruiting

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

Participants needed: 142
Trial details
Phase: Phase 4Age: 18+Biological sex: MaleType: InterventionalSponsor: Blue Earth DiagnosticsUpdated: Nov 5, 2026Locations: 6
Eligibility criteria

Participants must be males aged ≥18 years at Screening. [+5]

Participants with known metastatic castrate resistant prostate cancer. [+6]

Status: Recruiting

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer: The VIOLETTA Trial

This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

Participants needed: 110
Trial details
Age: 50+Biological sex: MaleType: InterventionalSponsor: Chinese University of Hong KongUpdated: Nov 6, 2026Locations: 1
Eligibility criteria

ISUP grade group 2 or 3 PCa [+2]

Status: Recruiting

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or proteins can predict which patients respond to the cancer treatment they receive. As tumors grow and begin to spread, they may release cells into patients' bloodstream. These cells are called "circulating tumor cells", or CTCs. CTCs can be used to look for differences in "biomarkers" (genes or proteins that may change based on how a person is or is not responding to treatment). The purpose of this research study is to learn whether scientists can use biomarkers from CTCs to predict which tumors will respond to certain hormonal therapies. Participants will have blood collected and provide an archival sample from a previous tumor biopsy. The researchers will compare biomarkers from participants who responded well to treatment to those who responded poorly in order to answer the research question.

Participants needed: 120
Trial details
Age: 18+Biological sex: MaleType: ObservationalSponsor: Duke UniversityUpdated: Nov 6, 2026Locations: 3
Eligibility criteria

Histologically confirmed diagnosis of adenocarcinoma of the prostate. Patients w... [+8]

History of intercurrent or past medical or psychiatric illness including active... [+3]

Status: Recruiting

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Background: Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer. This will help them understand any changes in cells and genes. These changes might lead to the development and progression of prostate cancer. Researchers think the study could lead to new treatments. Objective: To understand the changes in cells and genes that lead to the development and progression of prostate cancer. This could lead to new treatments. Eligibility: Men ages 18 and older who have or are suspected to have prostate cancer Design: Participants will be screened with physical exam and medical history. Participants will send tissue blocks of their tumor, if possible. If not, they will provide unstained slides of tumor tissue. Participants may provide samples of blood, urine, saliva, and prostate secretions. Participants may have imaging tests. They will lie in a machine that takes pictures of their body. These tests include: MRI of the prostate CT of the abdomen and pelvis Chest x-ray Participants may need a biopsy or surgery for treatment of their cancer. If so, researchers will collect tissue. Participants may answer questions about their prostate cancer and quality of life. Participants may have follow-up visits or other treatments. They may have follow-up phone calls every few months.

Participants needed: 3,000
Trial details
Age: 18+Biological sex: MaleType: ObservationalSponsor: National Cancer Institute (NCI)Updated: Nov 5, 2026Locations: 1
Eligibility criteria

Adults (greater than or equal to 18 years of age) with biopsy-proven or suspecte... [+7]

Status: Recruiting

Collection of Blood From Patients With Prostate Cancer

Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role. * Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene. * Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others. Objectives: -To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state. Eligibility: -All participants participating in NCI prostate cancer protocols. Design: * Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic. * Blood samples are collected at the initial visit or at follow-up visits. * DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines. * Gene variations are correlated with prostate cancer prognosis and prognostic indicators.

Participants needed: 1,000
Trial details
Age: 18+Biological sex: MaleType: ObservationalSponsor: National Cancer Institute (NCI)Updated: Nov 5, 2026Locations: 1
Eligibility criteria

Not listed

Status: Recruiting

Collection of Blood From Patients With Cancer

This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. ...

Participants needed: 1,750
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: National Cancer Institute (NCI)Updated: Nov 5, 2026Locations: 1
Eligibility criteria

Not listed

Status: Recruiting

Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

The goal of this phase 3 clinical trial is to determine the clinical effectiveness and cost effectiveness of using lower doses of Androgen Receptor Pathway Inhibitors (ARPI) to treat patients with prostate cancer that has spread (metastasized). The main questions it aims to answer are: 1. if overall survival for reduced dose ARPI is not worse than standard dose ARPI when treating patients with metastatic prostate cancer, and 2. that fatigue (extreme exhaustion) and not stopping ARPI permanently (due to adverse effects) are better than average with the reduced dose. Participants will: * Be randomised to take full dose (100%) of ARPI or half dose (50%) of ARPI. * Receive standard of care ADT. * Be on treatment for approximately 3 years according to standard of care. * Have clinic assessments and visits in clinic or remotely, as per their treating hospital's standard routine local practice in line with standard of care. Additional visits are not expected. * Complete quality of life questionnaires at week 0 (pre-treatment) and weeks 4, 16, 32, 48 and 64. * Keep a diary of their symptoms. Translational research samples will be collected as follows: * Blood samples at week 0 (pre-treatment) and weeks 24, 32, 48 and at disease progression. * Urine samples at week 0 (pre-treatment) and week 24 and at disease progression. * FFPE Tumour: Routinely collected diagnostic blocks. The duration of follow-up is approximately 3 years after the last patient is recruited (minimum follow-up is 3 years; maximum follow-up is approximately 6 years for the the first patient recruited) and the trial is expected to complete August 2032 (Last Patient Last Visit).

Participants needed: 1,500
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: University College, LondonUpdated: Nov 4, 2026Locations: 4
Eligibility criteria

Adult males (male sex at birth) aged 18 years or older [+4]

Pathology other than adenocarcinoma consistent with small cell, ductal, sarcomat... [+8]

Status: Not yet recruiting

A Study Comparing Single-Port and Multi-Port Robot-Assisted Surgery in Patients With Prostate or Kidney (Renal) Cancer

This is a prospective single-center observational study comparing single-port (SP) and multi-port (MP) robot-assisted surgery in adult patients undergoing robot-assisted radical prostatectomy (RARP) or robot-assisted partial nephrectomy (RAPN) for prostate or kidney cancer. Consecutive eligible patients will be managed according to routine clinical practice and assigned to SP or MP surgery based on predefined clinical and anatomical criteria, surgeon assessment, patient and tumor characteristics, platform availability, and surgical expertise. No randomization will be performed. The study aims to compare perioperative outcomes between the two surgical approaches, with length of hospital stay (LOS) as the primary endpoint. Secondary endpoints include intraoperative outcomes (operative time, estimated blood loss, and intraoperative complications), postoperative recovery, pain, postoperative complications, readmission rates, positive surgical margins, and hospital costs. Functional and patient-reported outcomes will also be evaluated, including urinary continence, sexual function, health-related quality of life, renal function after partial nephrectomy, decision regret, and cosmetic satisfaction.

Participants needed: 376
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: IRCCS San RaffaeleUpdated: Nov 4, 2026Locations: 1
Eligibility criteria

The participant provides written informed consent [+4]

Patients < 18 years [+5]

Status: Recruiting

A Study of Changes to Prostate Procedures

The purpose of this study is to look whether using local anesthesia during a transperineal prostate biopsy, while put to sleep by IV sedation, helps reduce the number of people who feel significant pain in the recovery room. The researchers will also look at how local anesthesia affects the amount of pain medication used, how quickly people can go home after the biopsy, and how well they recover after leaving the hospital.

Participants needed: 800
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Nov 5, 2026Locations: 7
Eligibility criteria

Patients scheduled for transperineal prostate biopsy at the JRSC or Monmouth. [+1]

None [+1]

Status: Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Participants needed: 460
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Nov 4, 2026Locations: 40
Eligibility criteria

Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell l... [+13]

Individual with known or suspected uncontrolled CNS metastases [+10]

Status: Recruiting

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Participants needed: 434
Trial details
Phase: Phase 3Age: 18+Biological sex: MaleType: InterventionalSponsor: ABX advanced biochemical compounds GmbHUpdated: Nov 4, 2026Locations: 19
Eligibility criteria

The patient (male) is aged 18 years or above. [+6]

Patients for whom radical prostatectomy is not clinically appropriate or the pat... [+10]

Status: Not yet recruiting

PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer

In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starting the trial.

Participants needed: 250
Trial details
Phase: Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: AHS Cancer Control AlbertaUpdated: Nov 4, 2026Locations: 1
Eligibility criteria

Participants capable of giving written informed consent. [+8]

Inability to complete the investigational imaging examinations due to other reas... [+6]

Status: Recruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.

Participants needed: 104
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Alliance for Clinical Trials in OncologyUpdated: Nov 4, 2026Locations: 30
Eligibility criteria

REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologicall... [+15]

Status: Recruiting

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Many people with cancer spend a lot of time and money traveling to and from the doctor's office for cancer care. MSK's goal is to make getting cancer care easier by cutting down the need to make in-person visits to MSK. MSK is trying to do this through a new option called enhanced telehealth.

Participants needed: 1,750
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Memorial Sloan Kettering Cancer CenterUpdated: Nov 3, 2026Locations: 7
Eligibility criteria

Patients with breast or prostate cancer at Memorial Sloan Kettering Cancer Cente...

Patient is enrolled on a therapeutic clinical trial. [+1]

Status: Recruiting

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.

Participants needed: 7,000
Trial details
Age: 40+Biological sex: AllType: ObservationalSponsor: Adela, IncUpdated: Nov 4, 2026Locations: 17
Eligibility criteria

Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagno... [+2]

Currently receiving any treatment for cancer [+12]

Status: Recruiting

Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer

The goal of this multicenter randomized controlled trial (RCT) is to evaluate the efficacy of different prostate biopsy schemes, including perilesional biopsy (PB) and combination of systematic biopsy and targeted biopsy (TB+SB). The main questions it aims to answer are: Does PB promote the accurate diagnosis of clinically significant prostate cancer? What's the value of PB in improving the safety of prostate biopsy? Researchers will compare the cancer detection rates of PB and TB+SB to explore the efficacy of different prostate biopsy schemes. Participants will: Receive TB+PB or TB+SB.

Participants needed: 640
Trial details
Age: 45-85Biological sex: MaleType: InterventionalSponsor: Peking University First HospitalUpdated: Nov 3, 2026Locations: 1
Eligibility criteria

The age of the patient is between 45 and 85. [+6]

The MRI data was unqualified or incomplete. [+7]

Status: Recruiting

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

To learn if the proposed dose of 177Lu rhPSMA-10.1 is safe. Phase 2 will open if the Phase 1 dose is found to be safe. To learn about the safety and effects of 177Lu rhPSMA-10.1 alone and with androgen deprivation therapy (ADT) on patients with high-risk, localized prostate cancer before they have surgery to remove the disease.

Participants needed: 6
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Nov 3, 2026Locations: 1
Eligibility criteria

Men ≥18 years of age [+28]

Prior hormone therapy for prostate cancer including orchiectomy, antiandrogens,... [+24]

Status: Recruiting

A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.

Participants needed: 152
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Aktis Oncology, Inc.Updated: Nov 2, 2026Locations: 2
Eligibility criteria

Age ≥ 18 years [+6]

Prior treatment with a B7-H3 targeted therapy [+5]

Status: Not yet recruiting

Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate

The COMFORT study will evaluate an artificial intelligence-based platform developed to support the clinical assessment of kidney and prostate cancer. The platform utilises imaging data to provide AI-generated outputs intended to assist clinicians in the assessment of suspected lesions. The primary objective of the study is to assess the role of the COMFORT platform in the clinical decision making process of clinicians managing kidney or prostate cancer cases. Secondary objectives include evaluation of the performance of AI models on anatomical segmentations, tumor characterisation (localisation, volumetric measurements, lesion classification, and scoring (e.g., Bosniak, PI-RADS, RENAL). Also the acceptability, usability, utility and trustworthiness of the AI models will be evaluated. In addition, potential causes of privacy leakage associated with the COMFORT AI models will be evaluated as part of the platform's privacy assessment.

Participants needed: 50
Trial details
Biological sex: AllType: ObservationalSponsor: Aristotle University Of ThessalonikiUpdated: Nov 2, 2026Locations: 6
Eligibility criteria

Healthcare professional resident or specialised in Urology [+2]